The drug Grafalon is used to prevent graft-versus-host disease in adults after hematopoietic stem cell transplantation.
Grafalon is indicated for the prevention of graft-versus-host disease in adults with hematologic malignancies following hematopoietic stem cell transplantation from matched unrelated donors in combination with standard prophylaxis with cyclosporine A and methotrexate.
Active ingredient: immunoglobulin
Prescription medicine.